Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CPB1 | P15086 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4386420 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL19437142 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL4379957 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL3203924 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL3204209 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL3219056 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL3223441 | 0.90 | ALDH1A1 (0.53) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL8886224 | 0.89 | ALDH1A1 (0.49) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL2553798 | 0.88 | ALDH1A1 (0.48) | ALDH1A1GAACPB1TSHREPHX1 | |
| SCHEMBL13643316 | 0.88 | CPB1 (0.50) | ALDH1A1GAACPB1TSHREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| EP-3820574-B1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | disclosed |
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230037639-A1 | 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NPY2R, NPY5R, RXFP1 | ALDH1A1 386/4885GAA 2695/4885CPB1 3019/4885 |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | ALDH1A1 470/4885GAA 2893/4885CPB1 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.